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Abstract Adverse neonatal outcomes continue to be high for
mothers with type 1 and type 2 diabetes, and are far from
eliminated in mothers with gestational diabetes mellitus.
This is often despite seemingly satisfactory glycaemic control
in the latter half of pregnancy. Here we argue that this could be a
consequence of the early establishment of fetal hyperinsulinaemia,
a driver that exaggerates the fetal glucose steal. Essentially, fetal
hyperinsulinaemia, through its effect on lowering fetal glycaemia,
will increase the glucose concentration gradient across the placenta
and consequently the glucose flux to the fetus.While the steepness
of this gradient and glucose flux will be greatest at times when
maternal hyperglycaemia and fetal hyperinsulinaemia coexist, fe-
tal hyperinsulinaemia will favour a persistently high glucose flux
even at times when maternal blood glucose is normal. The obvi-
ous implication is that glycaemic control needs to be optimised
very early in pregnancy to prevent the establishment of fetal
hyperinsulinaemia, further supporting the need for pre-
pregnancy planning and early establishment of maternal
glycaemic control. An exaggerated glucose steal by a
hyperinsulinaemic fetus could also attenuate maternal glucose
levels during an OGTT, providing an explanation for why some
mothers with fetuses with all the characteristics of diabetic
fetopathy have ‘normal’ glucose tolerance.
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Introduction
Despite significant advances in glycaemic control in the man-
agement of diabetes in pregnancy, adverse outcomes for the
fetus are still very common, particularly for pre-existing type 1
and type 2 diabetes. For example, in a recent review of 12
studies comprising 14,099 type 1 diabetic pregnancies the
RRs conferred by diabetes over the background population
for perinatal mortality, congenital malformations and preterm
birth were all significantly increased (3.7, 2.4 and 4.2, respec-
tively) [1]. Of particular note, 54.2% of neonates of type 1
diabetic pregnancies were born large for gestational age
(LGA) compared with 10.0% in the background population—
RR of 4.5 [1]. In addition, in gestational diabetes mellitus
(GDM), standard approaches to treatment, while reducing
the rates of LGA, do not fully normalise neonatal outcomes,
including the rates of neonatal hypoglycaemia, raised cord
blood C-peptide levels and neonatal fat mass [2–4].
In this article we propose that an exaggerated fetal glucose
steal phenomenon, driven by fetal hyperinsulinaemia, contrib-
utes to diabetic fetopathy, including excessive fetal fat accre-
tion. After introducing the glucose steal phenomenon, we re-
view what is known about the early development of insulin
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secretion in the fetus. We then discuss the need for tight glu-
cose control in the first and early second trimesters to prevent
fetal hyperinsulinaemia and exaggeration of the glucose steal
with its implications for the fetus.
The principle of the fetal glucose steal phenomenon
in normal and diabetic pregnancies
In considering determinants of glucose transfer from mother
to fetus, we focus mostly on those of the mother rather than
those of the fetus. Maternal glucose metabolism adapts to
pregnancy so as to provide a continuous supply of glucose
to the fetus. These hormone-regulated adaptations include in-
creased hepatic glucose production in the fasting state, to en-
sure a glucose supply at all times, and maternal peripheral
insulin resistance, which spares glucose for the fetus [5].
Mentioned rarely is the role of the fetus (and placenta) and
its propensity to act as a glucose sink, stealing glucose from
the mother. This process has been termed the ‘fetoplacental
glucose steal phenomenon’ [6]. It was originally established in
sheep [7, 8] and elaborated in detail in the rat [6]. There is also
indirect evidence that it operates in humans [9, 10].
All available evidence suggests that the placenta is a passive
conduit for the proportion of maternal glucose destined to reach
the fetus, at least at the end of gestation [11]. Thus, the maternal-
to-fetal glucose flux is mostly dictated by the maternal-to-fetal
glucose concentration gradient, i.e. the glucose concentration
difference between the maternal and fetal compartments.
Therefore, any concentration change in either compartment will
modify the concentration gradient and affect glucose flux
(Fig. 1).
Maternal glucose concentrations are determined not only
by maternal factors such as the type of diabetes and how well
it is managed, but also by the rate of glucose uptake in the
fetus. Fetal glucose concentrations are determined by both
glucose appearance, by transplacental glucose transfer from
the mother, and glucose disappearance, by its uptake into fetal
tissues, the latter being influenced by fetal insulin levels, fetal
insulin sensitivity and fetal weight. Thus, factors on either side
of the placenta determining maternal and fetal glucose con-
centrations are determinants of the transplacental glucose gra-
dient (Fig. 1).
We propose that the fetal glucose steal phenomenon is exag-
gerated in diabetic pregnancies as a consequence of fetal
hyperinsulinaemia and, in addition to maternal factors, this steal
contributes to diabetic fetopathy. The hallmark of diabetic
fetopathy is fetal hyperinsulinaemia, which drives fetal fat accu-
mulation, very often resulting in an LGA birth. However, in-
creased adiposity can also occur in infants of diabetic women
who have normal birthweight [4].
Because of its dual role as a growth factor and anabolic
hormone, fetal insulin has long been recognised as the major
driver of excess adipose tissue deposition in fetuses of
mothers with diabetes [12, 13]. Diabetic pregnancies are as-
sociated with elevated fetal insulin levels due to increased
maternal glucose reaching the fetal circulation, which stimu-
lates insulin release from the fetal pancreas (Pedersen hypoth-
esis, Fig. 1). However, other insulin secretagogues such as
amino acids and, potentially, fatty acids may also contribute
[14, 15].
In newborns of diabetic mothers, glucose clearance into tis-
sues is much faster than in newborns from normal pregnancies,
often causing neonatal hypoglycaemia due to neonatal
hyperinsulinaemia [16]. Hyperinsulinaemia in the fetus is likely
also to accelerate glucose clearance into fetal tissues and in-
crease the fetal glucose steal. Thus, the maternal–fetal glucose
gradient can be steepened in diabetic pregnancy by both ma-
ternal (poor glycaemic control) and fetal (hyperinsulinaemia)
factors, resulting in increased glucose transfer to the fetus.
Furthermore, even in the presence of normal maternal glucose
levels, fetal hyperinsulinaemia will still lower fetal glucose
concentrations, sustaining a high glucose gradient and an ex-
aggerated glucose steal (Fig. 1).
Early development of fetal hyperinsulinaemia
The human pancreas begins to develop 4 weeks after concep-
tion, and first insulin deposits can be found between weeks 7
and 8 [17]. In vitro fetal pancreases release insulin as early as
11 weeks of gestation [18]. Amniotic fluid insulin (AFI),
which originates from loss into fetal urine, is just detectable
at 12 weeks [19] and more easily measurable from 14 weeks
onwards [20]. AFI can be used as a surrogate for fetal serum
insulin, as AFI measured at 31 weeks has been shown to be
highly correlated with cord blood insulin measured at birth
(r=0.853; p=0.0001) [9].
While neonatal hyperinsulinaemia as a consequence of ma-
ternal diabetes is well established to occur as determined by
the measurement of cord blood insulin or C-peptide from
samples collected immediately after delivery [21], its onset
in pregnancy is less well understood. It has long been thought
that the fetal pancreas is unresponsive to glucose changes
early in pregnancy [22]. While this appears to hold true for
normal pregnancies, the fetal pancreas of pregnant women
with diabetes is already sensitive to glucose in vitro at
12 weeks [18]. This explains why AFI levels can be elevated
before the diagnosis of GDM [20, 23]. Elevated AFI concen-
trations, beginning at 14 weeks, are associated not only with
the mother’s risk of developing GDM [20, 23] but also with
the risk of the fetus having a birthweight >90th centile [20].
The cause of early fetal hyperinsulinaemia is not fully un-
derstood; however, it is highly correlated with maternal
glycaemic control early in pregnancy, such that early maternal
hyperglycaemia in type 1 and type 2 diabetic pregnancies, and
most probably GDM, is likely to be the major driver. Roles for
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alterations in other maternal nutrient levels associated with by
diabetes, however, may also be important. The maternal dia-
betic state not only leads to beta cell hyperplasia in the fetus
[24, 25] but also seems to accelerate the maturation of the beta
cell stimulus–secretion coupling mechanism [26]. It is of note
that fat deposition in the fetus begins at around 14 weeks,
which is the time of onset of early fetal hyperinsulinaemia [27].
The importance of maternal metabolism in the first
trimester of pregnancy
The pathophysiological relationship between maternal glucose
and fetal neonatal adiposity mediated through fetal insulin
levels was proposed more than six decades ago [12] and has
recently been confirmed in a large cohort of non-diabetic wom-
en of different ethnicities [28]. This raises the question about
when in pregnancy the metabolic perturbations in the mother
begin to influence the fetus. While this large cohort study
established that it occurs at 24–28 weeks’ gestation [28], there
is evidence that earlier periods may play an important role.
Although body composition was not measured and, hence,
body fat was not an outcome, a continuous relationship be-
tween maternal fasting glucose measured as early as
9–10 weeks’ gestation and the risk of an LGA birth has been
shown [29]. Likewise, random blood glucose in the first trimes-
ter was positively correlated with proinsulin levels in the cord
blood [30]. The influence of early pregnancy glycaemia is also
seen in the reports of stronger associations of maternal first and
second trimester glycosylated haemoglobin levels, compared
with later measurements, with birthweight and occurrence of
LGA [1, 31–33]. Consistent also is the finding that excessive
fetal growth in pre-gestational diabetes is evident by serial ul-
trasound in many pregnancies from 18 to 24 weeks and that
those with established LGA prior to 30 weeks are most likely to
result in greater severity macrosomia at birth [31, 34, 35].
The period when the metabolic environment has an effect on
fetal growth may even extend to pre-pregnancy. The influence
of pre-pregnancy metabolic changes on fetal development may
be mediated through modification of oocyte metabolism [36],
predominantly of their mitochondria [37], through changing
early embryonic growth and later growth trajectories.
Clinical consequences of the fetal glucose steal
Glucose steal and associations of early and late pregnancy












Fig. 1 Maternal (M) glucose is transferred to the fetus (F) across the
placenta down a concentration gradient. The glucose gradient is determined
by both maternal and fetal glucose levels. Maternal high glucose (MHG)
and/or lower fetal glucose will steepen the gradient, leading to augmented
glucose flux into the fetus. MHG is a consequence of inadequate control of
maternal diabetes, which promotes increased glucose transfer to the fetus,
increased fetal blood glucose, increased stimulation of insulin release from
fetal islets and, consequently, fetal hyperinsulinaemia (FHI), as described
by Pedersen and Osler [12]. Importantly, FHI, by increasing the rate of
glucose utilisation by the fetus, will lower fetal glucose, thereby increasing
the steepness of the transplacental glucose gradient and the rate of glucose
transfer. In effect, MHG pushes glucose and FHI pulls glucose (the fetal
glucose steal) across the placenta to the fetus. The ensuing increased glu-
cose delivery from diabetic mothers, together with the FHI, stimulates fetal
triacylglycerol formation and the deposition of excess fetal adipose tissue
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above, stronger associations between early rather than late
pregnancy glycosylated haemoglobin levels with LGA are
often reported [1, 31–33]. This is not, however, a universal
finding of all studies, as some show a greater effect of third
trimester glycaemic control [38, 39]. Overall, these studies
emphasise the importance of optimal glycaemic control
through the whole of pregnancy to prevent diabetic fetopathy.
Poor glycaemic control early in pregnancy will result in the
establishment of fetal hyperinsulinaemia, causing an exaggerated
fetal glucose steal. As a consequence, the overactive glucose steal
will increase the disposal of maternal glucose into the fetus, thus
attenuating the levels of maternal hyperglycaemia. Importantly,
this effect of lowering maternal glucose driven by the fetus will
be greatest in pregnancies with the most hyperinsulinaemic
fetuses.
Thus, the challenge for many clinicians working in the field
of diabetes in pregnancy that seemingly tight late pregnancy
glycaemic control often fails to prevent diabetic fetopathy, at
least in type 1 and type 2 diabetic pregnancies, can be partly
explained by the fetal glucose steal. This is because fetal
hyperinsulinaemia will sustain an increased glucose gradient
across the placenta and the glucose steal, even at times of near-
normal maternal glycaemia.
Once fetal hyperinsulinaemia is established, however, contin-
ued maternal hyperglycaemia into the third trimester will likely
compound the effects of the fetal hyperinsulinaemia and glucose
steal on accelerated fetal growth, as the maternal–fetal glucose
gradient and glucose transfer to the fetus will be greater. This is
consistent with reports that show an effect of late pregnancy
glycaemia on the adverse outcome of LGA [38, 39].
Exaggerated glucose steal due to fetal hyperinsulinaemia:
risk of masking GDM diagnosis by OGTT Weiss et al
assessed changes in the OGTT from 25 to 31 weeks’ gestation
in women with GDM categorised according to the presence or
absence of fetal hyperinsulinaemia [9]. In women with GDM
without evidence of fetal hyperinsulinaemia, determined by
AFI <48.6 pmol/l, glucose tolerance deteriorated from 25 to
31 weeks’ gestation (Fig. 2). By contrast, in GDM women
with fetal hyperinsulinaemia (AFI >48.6 pmol/l), glucose tol-
erance improved during the same period (Fig. 2). This can be
explained by siphoning of the glucose to the fetus in women
with hyperinsulinaemic fetuses, due to the effects of an
increase in glucose steal activity [9]. The placentas of
hyperinsulinaemic, macrosomic fetuses might also have been
larger, such that increased placental glucose consumption
could also have contributed to the blunting of the OGTT
glucose rise observed in the mothers. Thus, there is a risk that
GDM will not be diagnosed in women with the most affected
fetuses. Consistent with this, seven of 21 (33%), compared
with none of 11 (0%), women with AFI >48.6 pmol/l,
compared with AFI <48.6 pmol/l, delivered neonates with
birthweight >4,000 g [9].
The data of Weiss et al are important for two reasons
(Fig. 2) [9]. First, they support the premise that an exaggerated
glucose steal phenomenon operates in diabetic pregnancies
complicated by fetal hyperinsulinaemia. Second, they provide
a reason why some women with fetuses with all the charac-
teristics of diabetic fetopathy are often found to have ‘normal’
glucose tolerance.
Can tight glycaemic control later in pregnancy reverse
fetal hyperinsulinaemia and the fetal glucose steal? The
findings that treatment of GDM from 24 to 28 weeks can signif-
icantly reduce the rate of LGA births suggest it is possible to
reverse fetal hyperinsulinaemia, at least when hyperglycaemia is
mild [2, 3]. However, the rate of neonatal hypoglycaemia need-
ing intravenous glucose therapy was not significantly reduced in
the GDM treatment arms [2, 3]. Furthermore, treatment did not
significantly reduce the rate of elevated cord C-peptide levels in
the study where this was measured [3]. Despite normalisation of
birthweight, management of GDM has not been shown to nor-
malise excess fetal adiposity [4]. Thus, fetal hyperinsulinaemia
appears to be difficult to normalise with the usual approach to
managing mild maternal hyperglycaemia [2, 3].
Interestingly, in a study in which treatment of GDM with
insulin was initiated according to the presence or absence of an
elevated AFI concentration, the rate of elevated cord blood C-
peptide levels in neonates was markedly reduced, suggesting
that there is some potential to reverse fetal hyperinsulinaemia
by targeting it in GDM pregnancies [40]. In pre-existing dia-
betes, however, when normalisation of maternal glucose levels
is very difficult to achieve, fetal hyperinsulinaemia is likely to
be much more difficult to reverse, as potentially even short






















Fig. 2 OGTTs were performed in 34 mothers with GDM at 25 and
31 weeks prior to any commencing insulin therapy. Amniocentesis was
also performed at week 31 and AFI levels were measured [9]. In the
mothers of the 13 normoinsulinaemic fetuses (AFI <48.6 pmol/l; solid
blue line), maternal glucose tolerance deteriorated from the first to the
second time point as manifested by a higher 1 h post-load glucose value
(9.3 vs 10.0 mmol/l; p = 0.0006). In the mothers of the 21
hyperinsulinaemic fetuses (AFI >48.6 pmol/l; dotted red line), the glu-
cose levels at 1 and 2 h of the repeated OGTTwere lower (significant for
the 1 h reading only) than at 25 weeks (1 h, 11.2 vs 9.9 mmol/l, p = 0.002;
2 h, 8.8 vs 7.7 mmol/l, p = 0.158) [9]. Figure created from data from
Weiss et al [9]
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association between hyperglycaemic spikes in the third trimes-
ter with LGAwould be consistent with this premise [38].
Future directions
Of major importance is an improved understanding of the
mechanisms causing early fetal hyperinsulinaemia, as this is
the driver that accelerates the fetal glucose steal in diabetic
pregnancy. While it may be a consequence of maternal
glycaemia only, other nutrients such as amino acids and fatty
acids and/or hormones/cytokines could also contribute, partic-
ularly in the pregnancies of obese mothers in whom glucose
tolerance is normal but cord blood C-peptide levels are shown
to be elevated at birth [41]. It will be particularly important to
determine the factors that render early glucose signalling com-
petence to fetal islets, as this occurs earlier in diabetic preg-
nancies. It is already known from elegant studies of the glu-
cokinase gene in the fetus that fetal genetic factors can alter the
responsiveness of fetal islets to maternal hyperglycaemia [42].
Improved understanding of fetal (including genetic and epige-
netic) factors that determine the likelihood of pathological
hyperinsulinaemia in the fetus will also be useful. The role
of the placenta in fetal nutrient supply early in pregnancy is
entirely unknown. In particular, studies should be undertaken
to address the question whether the placenta plays a passive,
permissive role or whether it actively contributes to determin-
ing the amount of nutrients that will be passed on to the fetus
in the early periods of gestation.
The discussion above has focused only on the fetal glucose
steal. It is highly conceivable that fetal hyperinsulinaemia could
also drive a fetal fatty acid and/or an amino acid steal.
Furthermore, an increased supply of fatty acids and amino acids
could contribute to the maintenance of fetal insulin hypersecre-
tion and fetal hyperinsulinaemia in situations where maternal
glucose levels are relatively well controlled. A fetal fatty acid
steal is clearly conceivable, at least for those fatty acids which
are transferred by diffusion [43]. For other fatty acids and ami-
no acids the more complex transplacental transfer mechanisms
may make a steal phenomenon more complicated.
The high likelihood that fetal hyperinsulinaemia can mask
an OGTT diagnosis of GDM through the glucose steal phe-
nomenon requires further confirmation and the clinical conse-
quences need thorough consideration. New methodologies to
reliably diagnose the presence of fetal hyperinsulinaemia
should also be sought, potentially to indicate the degree of
aggressiveness required to improvematernal metabolic control.
Randomised controlled clinical trials focusing on optimi-
sation of glycaemic and metabolic control prior to and during
the first trimester of pregnancy in disorders of mild
hyperglycaemia, or in women who are overweight and obese
even with normoglycaemia, are required to determine whether
this can prevent fetal hyperinsulinaemia and excess fetal
growth.
Finally, to further improve pregnancy outcomes related to
fetal hyperinsulinaemia and exaggeration of the fetal glucose
steal in pre-existing type 1 and type 2 diabetes, as well as in
GDM, it is necessary to optimise metabolic control early in
pregnancy. This will necessitate pre-pregnancy planning for
women with pre-existing diabetes, as well as for those at in-
creased risk of GDM, and better means to safely normalise
glycaemia.
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